Given that G-CSF is reportedly elevated in the sputum, serum, and BALF of COPD patients [18–20], our findings suggest that G-CSF plays a key role in the differentiation of pathogenic Siglec-F+ neutrophils and could serve as a promising therapeutic target for patients with emphysema. Here, CSF3 is linked to pulmonary emphysema.